Maintaining mood stability in bipolar disorder: A clinical perspective on pharmacotherapy

Evidence-Based Mental Health

Volumn 18, Issue 1, 2015, Pages 1-7

  Malhi, Gin S ^a,b   McAulay, Claire ^a,b   Das, Pritha ^a,b   Fritz, Kristina ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; TRANQUILIZER;

AFFECT; BIPOLAR DISORDER; DRUG COMBINATION; HUMAN; MEDICATION COMPLIANCE; PSYCHOLOGY; RECURRENT DISEASE;

AFFECT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; HUMANS; MEDICATION ADHERENCE; RECURRENCE;

EID: 84921732218     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/eb-2014-101948     Document Type: Article

References (47)

1. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445–57.
2. Miklowitz DJ, Gitlin MJ. Clinician’s Guide to Bipolar Disorder: Integrating Pharmacology and Psychotherapy. New York: Guildford Publications, 2014:113–44.
3. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord 2012;14(Suppl 2):51–65.
4. Malhi GS, Bargh DM, McIntyre R, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012;14(Suppl 2):1–21.
5. Goldberg JF, Harrow M. A 15-year prospective follow-up of bipolar affective disorders: comparisons with unipolar nonpsychotic depression. Bipolar Disord 2011;13:155–63.
6. Popovic D, Reinares M, Goikolea JM, et al. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012;22:339–46.
7. Malhi GS, Adams D, Lampe L et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009;119:27–46.
8. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217–24.
9. Degenhardt EK, Gatz JL, Jacob J, et al. Predictors of relapse or recurrence in bipolar I disorder. J Affect Disord 2012;136:733–9.
10. Goodwin FK, Whitham EA, Ghaemi SN. Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? CNS Drugs 2011;25:819–27.
11. Cipriani A, Barbui C, Rendell J, et al. Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatr Scand 2014;129:328–42.
12. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs 2013;27:515–29.
13. Vieta E, Günther O, Locklear J, et al. Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2011;14:1029–49.
14. Cipriani A, Reid K, Young AH, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder (review). Cochrane Database Syst Rev 2013;10:CD003196. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003196/ pdf/standard (accessed 23 Jul 2014).
15. Malhi GS, Tanious M, Das P, et al. The science and practice of lithium therapy. Aust N Z J Psychiatry 2012;46:192–211.
16. Grof P. Excellent lithium responders: people whose lives have been changed by lithium prophylaxis. In: Birch N, Gallichio V, Becker R, eds. Lithium: 50 years of psychopharmacology. New perspectives in biomedical and clinical research. Cheshire, CT: Weidner Publishing Group, 1999:36–51.
17. Malhi GS, Tanious M, Das P, et al. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013;27:135–53.
18. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375:385–95.
19. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004;65:432–41.
20. Licht RW, Nielsen JN, Gram LF, et al. Lamotrigine versus lithium as maintenance treatment in bipolar I disorder: an open, randomized effectiveness study mimicking clinical practice. The 6th trial of the Danish University Antidepressant Group (DUAG-6). Bipolar Disord 2010;12:483–93.
21. van der Loos ML, Mulder P, Hartong EG, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord 2011;13:111–17.
22. Chen CH, Lin SK. Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes. BMC Psychiatry 2012;12:47.
23. Weisler RH, Nolen WA, Neijber A, et al. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry 2011;72:1452–64.
24. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160:1263–71.
25. Cipriani A, Rendell JM, Geddes J. Olanzapine in long-term treatment for bipolar disorder (review). Cochrane Database Syst Rev 2009;(1):CD004367.
26. Missio G, Moreno DH, Fernandes F, et al. The ARIQUELI study: potentiation of quetiapine in bipolar I nonresponders with lithium versus aripiprazole. Trials 2013;14:190.
27. Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord 2011;128(Suppl):S21–8.
28. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 2013;147:365–72.
29. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249–62.
30. Valentí M, Pacchiarotti I, Bonnín CM, et al. Risk factors for antidepressant-related switch to mania. J Clin Psychiatry 2012;73:e271–6.
31. Burgess S, Geddes J, Hawton K, et al. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001;(3):CD003013.
32. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997;58:470–8.
33. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003;63:2029–50.
34. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481–9.
35. Zupancic M, Gonzalez ML. Aripiprazole in the acute and maintenance phase of bipolar I disorder. Ther Clin Risk Manag 2012;8:1–6.
36. Weisler RH, Montgomery SA, Earley WR, et al. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies. Int Clin Psychopharmacol 2012;27:27–39.
37. Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9:413–25.
38. Chiesa A, Chierzi F, De Ronchi D, et al. Quetiapine for bipolar depression: a systematic review and meta-analysis. Int Clin Psychopharmacol 2012;27:76–90.
39. Quiroz JA, Yatham LN, Palumbo JM, et al. Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010;68:156–62.
40. Macfadden W, Alphs L, Haskins JT, et al. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently. Bipolar Disord 2009;11:827–39.
41. Bowden CL, Vieta E, Ice KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71:130–7.
42. Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009;11(Suppl 2):55–76.
43. Marangell LB, Dennehy EB, Miyahara S, et al. The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD. J Affect Disord 2009;114:58–67.
44. Scott J, Colom F, Vieta E. A meta-analysis of relapse rates with adjunctive psychological therapies compared to usual psychiatric treatment for bipolar disorders. Int J Neuropsychopharmacol 2007;10:123–9.
45. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381:1672–82.
46. Malhi GS, Bargh DM, Cashman E, et al. The clinical management of bipolar disorder complexity using a stratified model. Bipolar Disord 2012;14(Suppl 2):66–89.
47. Berk M, Copolov DL, Dean O, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008;64:468–75.